This presentation contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2018. The forward-looking statements in this presentation are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
Milestone Scientific designs, patents, incubates and commercializes a growing portfolio of innovative medical and dental technologies.

**COMPANY**

<table>
<thead>
<tr>
<th><strong>NYSE MKT:</strong></th>
<th>MLSS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Founded:</strong></td>
<td>1991</td>
</tr>
<tr>
<td><strong>Employees:</strong></td>
<td>16</td>
</tr>
<tr>
<td><strong>Headquarters:</strong></td>
<td>NJ</td>
</tr>
</tbody>
</table>

**TECHNOLOGY**

Proprietary Dynamic Pressure Sensing (DPS) Technology® platform at the core of dental and medical portfolio - monitors pressure at the tip of a needle for more precise delivery of anesthesia

**PRODUCTS**

**Commercial:**
- The Wand® STA
- CompuFlo® Epidural
- CompuFlo® Intra-articular
- CompuFlo® Trainer

**Pipeline:**
- Peripheral Nerve Block
- Cosmetic
INVESTMENT HIGHLIGHTS

- DPS platform can be customized for a variety of medical and dental applications
- Solid IP: 20 U.S. patents and growing
- Recurring revenue model

<table>
<thead>
<tr>
<th><strong>DENTAL</strong></th>
<th><strong>MEDICAL</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>FDA and CE marketing clearance in over 50 countries</td>
<td>Growing sales pipeline in labor &amp; delivery; following published data from three clinical trials</td>
</tr>
<tr>
<td>Over 90M worldwide injections delivered to date</td>
<td>Over 1,800 epidural procedures worldwide to date with CompuFlo®</td>
</tr>
<tr>
<td>Avg. $10M+ revenues past 3 years</td>
<td>Newly launched CompuFlo® Trainer for medical education market; global distribution agreement with 3B Scientific</td>
</tr>
<tr>
<td>Exclusive 10-year distribution with Henry Schein in US &amp; Canada</td>
<td>Total Addressable Market: Of the 4.4 million annual US births, only 2.4 million utilize epidurals due to complications</td>
</tr>
<tr>
<td>Total Addressable Market: 150,000 dentists in U.S. and Canada to perform 2.2M injections this year</td>
<td>Received peripheral nerve block patent</td>
</tr>
</tbody>
</table>
The hypodermic syringe was invented over 160 years ago.

**The Problem**
- Pain
- Discomfort
- Anxiety
- Post-Injection Necrosis

**The Solution**
- Painless Injection
- Comfort
- Precise Injection
- Safety

*Milestone’s Patented DPS® Dynamic Pressure Sensing Technology*
Real-time Dynamic Pressure Sensing® (DPS) Technology

- Milestone’s proprietary DPS technology is the core of the company’s product portfolio

- DPS is the first technology to monitor — at the tip of a needle — pressure changes that are imperceptible by touch

- This allows DPS to objectively, accurately and reliably detect tissues of the body, allowing for a precise injection of medication at an intended, exact location

- Beyond dental, Milestone has identified medical opportunities for many high-impact, next-generation applications of our patented technology
IT BEGAN WITH DENTAL - THE WAND®

For Clinicians:
- Anesthetize a single tooth
- Reduction in chair time
- Reduced quantity of anesthetic
- Fewer complications
- Ergonomic grip
- Reduced patient cancellations
- Avoid tachycardia

For Patients:
- Painless injection
- No collateral numbness
- Faster onset of anesthesia
THE WAND® SINGLE TOOTH ANESTHESIA INSTRUMENT

- FDA and CE marketing clearance in over 50 countries
- Over 90M injections delivered to date
  - $10M revenues in 10 major markets: average over past 3 years
- Key Opinion Leader recognition worldwide
- Included in dental school curriculum as best practice
- International roll-out of digital marketing plan underway
- 20 patents around DPS® Dynamic Pressure Sensing technology

Wand Dental subsidiary is cash flow positive on a standalone basis
Announced a 10-year exclusive agreement with Henry Schein, Inc. (NASDAQ: HSIC), in June 2016
- The world's largest provider of dental products

Henry Schein's Exclusive Products Sales Specialist Team will exclusively market and distribute The Wand® STA®
- 25 sales representatives supported by 900 field service representatives
- Minimum purchase orders to maintain exclusivity in the third through tenth years

Total Addressable Market: About 150,000 dentists in the USA and Canada will perform about 2.2M injections this year alone
2018 results reflect reallocation of resources to the Medical Division
Dental Division achieved 8% YOY growth to $1.9 million with 68% GM for Q1 2019
THE FUTURE
Epidural Training Peripheral Nerve Block Intra-articular

- Building sales pipeline for the FDA-cleared CompuFlo® Epidural Instrument in labor and delivery; following published data from three clinical trials
- Strong market demand in thoracic due to high-risk nature of procedure; 3 – 5 % of all epidurals; Thoracic CE mark in progress
- Large academic institution committed to publishing a thoracic study with IRB secured, data collection beginning in April 2019
- Developed CompuFlo® Trainer a non-human version of the clinical instrument dedicated to medical training
- Signed distribution agreement with American 3B Scientific for the simulator and academic training center market
- Received peripheral nerve block patent
- Form of regional anesthesia that has significantly increased in use for the highly-sensitive treatment of trauma and surgical procedures
- Received CE mark for intra-articular instrument
- Precise joint injections in arthritic areas such as hips and knees
TOTAL ADDRESSABLE MARKET: > $1B IN THE USA ALONE

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Application Area</th>
<th># Procedures per Year (millions)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epidural</td>
<td>Labor &amp; Delivery</td>
<td>4.4/2.4*</td>
</tr>
<tr>
<td></td>
<td>Periop Pain Management</td>
<td>3.0</td>
</tr>
<tr>
<td></td>
<td>Chronic Pain</td>
<td>8.0</td>
</tr>
<tr>
<td>Peripheral Nerve Block</td>
<td></td>
<td>9.0</td>
</tr>
<tr>
<td>Intra-articular</td>
<td>Knees</td>
<td>2.5</td>
</tr>
<tr>
<td></td>
<td>Shoulders</td>
<td>1.5</td>
</tr>
<tr>
<td></td>
<td>Hips/Other</td>
<td>1.0</td>
</tr>
<tr>
<td>Cosmetic</td>
<td>Botox</td>
<td>8.4</td>
</tr>
<tr>
<td>TOTAL</td>
<td></td>
<td>37.8/35.8 million</td>
</tr>
</tbody>
</table>

Company estimates derived from CDC, CMS, NCHS, AHRQ, NVSS, ASPS, and ASDS data
*Of the 4.4 million annual US births, only 2.4 million utilize epidurals due to complications
EPIDURAL ANESTHESIA APPLICATION

- An epidural is the injection of drugs through a catheter placed into the epidural space.

- It can result in a loss of sensation — including the sensation of pain — by blocking signals in or near the spinal cord.

- Depending on geographic location, 70 to 80% of women get labor epidural analgesia.
Reached enrollment of 400 patients in two separate arms:
(i) pain management (240); (ii) labor & delivery – L&D (160)
99% effective in identifying epidural space on first attempt
14% more successful in patients with high body mass index
L&D epidurals resulted in 0 dural punctures, 4 with loss of resistance, syringe (old technology)
Procedure time reduced by 25% with CompuFlo
COMPUFLO® EPIDURAL STUDY
– ANESTHESIOLOGY RESEARCH & PRACTICE, JAN 2019

- 120 patient clinical study
- CompuFlo® blocks performed successfully with no complications
- Consistent differentiation of true loss of resistance

“The pressure sensing innovation in CompuFlo offers a more objective, reliable and simpler way to identify the epidural space. This confidence in recognizing a true loss of resistance can help improve the efficacy of anesthesia, reduce complications, and speed the procedure learning curve for trainees.”

Dr. Giorgio Capogna, Director of the European School of Obstetric Anesthesia and Maternal Neonatal Simulation Center
Objective identification of ligamentum flavum and epidural space

Difficult blocks rescued in a single attempt

Differentiation of true loss of resistance for accurate epidural placement

“We validated the CompuFlo device as a means of adequately identifying the ligamentum flavum and the epidural space. Our preliminary findings suggest that it could assist the physician in training when performing epidural insertion.”

Study investigators from the Citta di Roma Hospital and Careggi Hospital: Dr. Giorgio Capogna, Dr. Michela Camorcia, Dr. Alessandra Coccoluto, Dr. Massimo Micaglio, Dr. Matteo Velardo
Three peer-reviewed studies validate instrument effectiveness in identifying epidural space

More than 1,800 epidural procedures performed worldwide by key opinion leaders

- KOL relationship development in progress in France, Spain, Germany, UK, Belgium, Italy, US
- One anesthesiologist completed 600 CompuFlo® epidurals, reporting no dural punctures
- First hospital in Italy adopts CompuFlo® for all epidurals in labor and delivery
- Nine new distributors added in the U.S. to expand sales network; 70 sales professionals on the street, 12 trained to-date to cover cases clinically

Tradeshow Product Awareness at six industry events: SOAP, OAA, ESA, ESRA, ASA, PGA

- 2 new clinical abstracts presented at ESA 2019
  - Madrid hospital finds CompuFlo a reliable technique for blood patch procedures
  - European School of Obstetric Anesthesia reports CompuFlo improves trainee success
COMPUFLO® EPIDURAL - INTERNATIONAL SALES

Signed Distributor Agreements

- MOVI Group in Italy
  - 10 instruments purchased
  - 1 dedicated product manager, 3 regional managers, 28 field sales agents
  - First sale to Ospedale Pugliese Ciaccio di Cantanzaro, hospital in Italy
  - Reorder of 500 disposable kits in June 2019
- EMA d.o.o. in Croatia
  - 3 instruments purchased
  - Trials in 4 hospitals
- Diagal in Algeria
  - 6 instruments purchased
- Sterimed in Lebanon
  - Presented at 3 congresses
  - Trials in 2 University hospitals
- REAN in Russia *MOU
  - 1 demo instrument purchased to investigate market size
  - Presented at 4 congresses

Pending

- Order: 5 instruments + 300 disposables to distributor in Turkey
- Agreements: Australia, Switzerland, Bosnia
COMPUFLO® EPIDURAL - US PRE-SALES

- Sales strategy to build pipeline
  - Demos leading to loaner trials to sales

- On-boarded 8 new distributors to expand the sales network
  - Signed large US stocking distributor, CTI, covering the Mid-West
    - Secured order for $32,500
  - 70 sales professionals on the street
  - 12 trained to-date to cover cases clinically

- Over 300 physician demos completed in 20 hospitals
  - 5 hospitals moved to immediate trial
  - 5 moved CompuFlo® to value-analysis committee (VAC)
  - 3 declined a trial
THE COMPUFLO® TRAINER

- Distribution Agreement with 3B Scientific (North, Central and South America), global distributor specializing in simulators
- New product entry in anesthesia training aimed at accelerating clinical instrument adoption
- Developed full educational suite of tools to support learning including “Skill Lab” online instruction help and “Procedure Log” to track trainee performance
- Delivered new product in record timing with simplified user interface and new multi-use disposables
- Unveiled at Euroanesthesia 2019

Connecting Technique & Intelligence

“Pairing 3B Scientific’s didactic learning materials and advanced simulators with CompuFlo’s objective verification is a game changer for training”

Zach Montgomery, Managing Director, American 3B Scientific
THE COMPUFLO® TRAINER BENEFITS

- Provides objective intelligence to shorten the learning curve
- Builds confidence by reducing the number of attempts
- Empowers instructors to visually and audibly monitor needle movement
- Generates procedure documentation to enhance skill development

Researchers from University of Texas Medical School at Houston found CompuFlo significantly improves trainee success rates when compared to use of traditional loss of resistance.
THE COMPUFLO® TRAINER VIDEO HIGHLIGHTS

https://youtu.be/7EJCa1OAigk

Milestone Scientific CompuFlo Epidural Trainer
UNDER DEVELOPMENT

**Intra-Articular**
- CE marketing clearance in EU

**Peripheral Nerve Block**
- Patent and work in progress

**Botulin Toxin Cosmetic**
- Under development
  - Accurate & comfortable stylus grip
  - Simple electronic records
INVESTMENT THESIS

- Wand Dental subsidiary is cash flow positive on standalone basis with continued growth opportunities; validates that the technology and business model works
- Proprietary disposables provide recurring revenue with high margins
- Entering medical markets with clinically proven indications for use
  - Epidural anesthesia instrument is cleared in the USA and EU
  - Intra-articular instrument is cleared in EU and in process in the USA
  - New product entry in anesthesia training
  - Cosmetic instrument under development
- Scalable business model
  - High incremental margins with growing revenue
- Value Drivers 2019/2020:
  - Operating results
  - Distribution and marketing contracts
NYSE: MLSS

KEY STATISTICS AS OF MARCH 31, 2019

- Ticker: MLSS
- Exchange: NYSE
- Share Price (7/3/19): $0.43
- Shares Outstanding: 41.1 M
- Cash and Treasury Bills: $2.7 M
- Working Capital: $2.1 M
- Total Shareholder’s Equity: $2.7 M
- Security Ownership of Management: 31.5%
THANK YOU